Send to

Choose Destination
Ther Adv Med Oncol. 2016 Jan;8(1):57-84. doi: 10.1177/1758834015614530.

Pharmacologic resistance in colorectal cancer: a review.

Author information

Division of Hematology/ Oncology, Mayo Clinic, Jacksonville, FL, USA.
Division of Hematology/ Oncology, Mayo Clinic Cancer Center, Mayo Clinic, 4500 San Pablo Rd S, Jacksonville, FL 32224, USA.


Colorectal cancer (CRC) persists as one of the most prevalent and deadly tumor types in both men and women worldwide. This is in spite of widespread, effective measures of preventive screening, and also major advances in treatment options. Despite advances in cytotoxic and targeted therapy, resistance to chemotherapy remains one of the greatest challenges in long-term management of incurable metastatic disease and eventually contributes to death as tumors accumulate means of evading treatment. We performed a comprehensive literature search on the data available through PubMed, Medline, Scopus, and the ASCO Annual Symposium abstracts through June 2015 for the purpose of this review. We discuss the current state of knowledge of clinically relevant mechanisms of resistance to cytotoxic and targeted therapies now in use for the treatment of CRC.


colon adenocarcinoma; colon cancer; resistance

Supplemental Content

Full text links

Icon for PubMed Central
Loading ...
Support Center